Australian Comparative Trial of the effect of Angiotensin-Converting Enzyme (ACE) Inhibitor and Diuretic-based Treatment of Hypertension on rates of cardiovascular-associated mortality in the Elderly

High Blood Pressure Research Council of Australia0 个研究点目标入组 6,083 人开始时间: 2022年3月8日最近更新: 2022年3月14日

适应症

试验速览

暂无简介。

•Are 65-84 years of age
•- Confirmed hypertension, either untreated or previously treated, with average untreated sitting blood pressure on the 2nd and 3rd screening visits of the study greater than or equal to 160 mmHg or greater than or equal to90 mmHg diastolic (if systolic BP is greater than or equal to 140 mmHg)
•- Have no history of recent cardiovascular morbidity (see under exclusion criteria), serious intercurrent illness or a absolute contraindication to an ACE inhibitor or diuretic
•- Are capable of and willing to give informed consent
•- Are ambulant and able to attend their general practitioner's practise throughout the study

•- Prescence of any previous nonfatal cardiovascular event which defines an end-point for the study in the past 6 months. Refers to any existing condition (eg cancer) which the GP feels is likely to cause death with 5 years.
•- Accelerated or malignant hypertension
•- Dementia
•- Plasma creatinine concentration > 0.2mmol/l. The measurement should have been within the past 12 months or, if this is not available, will be undertaken at the initial screening visit
•- Any life threatening illness considered to be likely to cause death within the study's observation period (5 years)
•- Presence of any absolute contraindication to or specific indication for an ACE inhibitor or a diuretic
•- Consideration by the subject's general practitioner that the subject is unsuitable for the study

发起方

High Blood Pressure Research Council of Australia